BAKER BROS. ADVISORS LP — ACADIA PHARMACEUTICALS INC. ACAD: Quarterly 13F Position History
BAKER BROS. ADVISORS LP has reported ACADIA PHARMACEUTICALS INC. (ACAD) on 41 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2016. As of Q1 2026, the position is sized at 42,896,690 shares ($954.9M market value, 5.48% of the equity book).
- 42,896,690Shares Held (Latest Filing)
- $954.9MReported Market Value (Latest Filing)
- 5.48%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$190.9MQuarter-over-Quarter Value Change
- 42,896,690Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 42,896,690 | 0 | — | $954.9M | 5.48% | $22.26 |
| Q4 2025 | 42,896,690 | 0 | — | $1.15B | 6.71% | $26.71 |
| Q3 2025 | 42,896,690 | 0 | — | $915.4M | 6.61% | $21.34 |
| Q2 2025 | 42,896,690 | +18,774 | +0.0% | $925.3M | 8.98% | $21.57 |
| Q1 2025 | 42,877,916 | 0 | — | $712.2M | 7.88% | $16.61 |
| Q4 2024 | 42,877,916 | 0 | — | $786.8M | 8.40% | $18.35 |
| Q3 2024 | 42,877,916 | 0 | — | $659.5M | 6.83% | $15.38 |
| Q2 2024 | 42,877,916 | +13,304 | +0.0% | $696.8M | 8.90% | $16.25 |
| Q1 2024 | 42,864,612 | 0 | — | $792.6M | 9.94% | $18.49 |
| Q4 2023 | 42,864,612 | 0 | — | $1.34B | 15.27% | $31.31 |
| Q3 2023 | 42,864,612 | 0 | — | $893.3M | 5.15% | $20.84 |
| Q2 2023 | 42,864,612 | +926,126 | +2.2% | $1.03B | 5.94% | $23.95 |
| Q1 2023 | 41,938,486 | +15,000 | +0.0% | $789.3M | 4.29% | $18.82 |
| Q4 2022 | 41,923,486 | 0 | — | $667.4M | 4.01% | $15.92 |
| Q3 2022 | 41,923,486 | 0 | — | $685.9M | 4.49% | $16.36 |
| Q2 2022 | 41,923,486 | +12,782 | +0.0% | $590.7M | 3.35% | $14.09 |
| Q1 2022 | 41,910,704 | 0 | — | $1.02B | 5.83% | $24.22 |
| Q4 2021 | 41,910,704 | 0 | — | $978.2M | 4.76% | $23.34 |
| Q3 2021 | 41,910,704 | 0 | — | $696.1M | 3.06% | $16.61 |
| Q2 2021 | 41,910,704 | 0 | — | $1.02B | 4.49% | $24.39 |
| Q1 2021 | 41,910,704 | +6,118 | +0.0% | $1.08B | 4.69% | $25.80 |
| Q4 2020 | 41,904,586 | 0 | — | $2.24B | 8.44% | $53.46 |
| Q3 2020 | 41,904,586 | 0 | — | $1.73B | 6.91% | $41.25 |
| Q2 2020 | 41,904,586 | 0 | — | $2.03B | 8.96% | $48.47 |
| Q1 2020 | 41,904,586 | +1,050,000 | +2.6% | $1.77B | 10.90% | $42.25 |
| Q4 2019 | 40,854,586 | 0 | — | $1.75B | 9.29% | $42.78 |
| Q3 2019 | 40,854,586 | +1,562,500 | +4.0% | $1.47B | 10.00% | $35.99 |
| Q2 2019 | 39,292,086 | 421,756 | -1.1% | $1.05B | 7.14% | $26.73 |
| Q1 2019 | 39,713,842 | 0 | — | $1.07B | 6.83% | $26.85 |
| Q4 2018 | 39,713,842 | +11,274,728 | +39.6% | $642.2M | 5.26% | $16.17 |
| Q3 2018 | 28,439,114 | +1,210,776 | +4.4% | $590.4M | 3.89% | $20.76 |
| Q2 2018 | 27,228,338 | 0 | — | $415.8M | 3.12% | $15.27 |
| Q1 2018 | 27,228,338 | 0 | — | $611.8M | 5.19% | $22.47 |
| Q4 2017 | 27,228,338 | +1,408,570 | +5.5% | $819.8M | 7.11% | $30.11 |
| Q3 2017 | 25,819,768 | 0 | — | $972.6M | 7.89% | $37.67 |
| Q2 2017 | 25,819,768 | 0 | — | $720.1M | 6.30% | $27.89 |
| Q1 2017 | 25,819,768 | 0 | — | $887.7M | 7.26% | $34.38 |
| Q4 2016 | 25,819,768 | 0 | — | $744.6M | 7.30% | $28.84 |
| Q3 2016 | 25,819,768 | +1,303,030 | +5.3% | $821.3M | 7.45% | $31.81 |
| Q2 2016 | 24,516,738 | +302,900 | +1.3% | $795.8M | 8.34% | $32.46 |
| Q1 2016 | 24,213,838 | — | — | $677.0M | 7.14% | $27.96 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a ACAD position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported ACADIA PHARMACEUTICALS INC. (ACAD) on its 13F-HR filing for the period ending 2016-03-31 (Q1 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in ACAD?
BAKER BROS. ADVISORS LP held the same 42,896,690 shares of ACAD between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in ACAD?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.